Modafinil for people with schizophrenia or related disorders: a Cochrane Review
Regarding the effect of modafinil on cognitive function, the trials did not report clinically important change data, but one study reported endpoint scores on the MATRICS Consensus Cognitive Battery (MCCB): in this study we found no clear difference in scores between modafinil and placebo treatment...
Gespeichert in:
| Veröffentlicht in: | BJPsych advances 2022-09, Vol.28 (5), p.280-280 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 280 |
|---|---|
| container_issue | 5 |
| container_start_page | 280 |
| container_title | BJPsych advances |
| container_volume | 28 |
| creator | Ortiz-Orendain, Javier Covarrubias-Castillo, Sergio A. Vazquez-Alvarez, Alan Omar Castiello-de Obeso, Santiago Arias Quiñones, Gustavo E. Seegers, Maya Colunga-Lozano, Luis Enrique |
| description | Regarding the effect of modafinil on cognitive function, the trials did not report clinically important change data, but one study reported endpoint scores on the MATRICS Consensus Cognitive Battery (MCCB): in this study we found no clear difference in scores between modafinil and placebo treatment groups (MD −3.10, 95% CI −10.9 to 4.7; participants = 48; studies = 1, very low-quality evidence). None of the trials reported clinically important change in quality of life, but one study did report quality of life using endpoint scores on the Quality of Life Inventory, finding no clear difference between treatment groups (MD −0.2, 95% CI −1.18 to 0.78; participants = 20; studies = 1, very low-quality evidence). [...]one study reported data for number of participants needing hospitalisation: one participant in each group was hospitalised (RR 0.84, 95% CI 0.06 to 12.42; participants = 35; studies = 1, very low-quality evidence). |
| doi_str_mv | 10.1192/bja.2022.37 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2707470022</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cupid>10_1192_bja_2022_37</cupid><sourcerecordid>2707470022</sourcerecordid><originalsourceid>FETCH-LOGICAL-c187t-5b9e217e05277f5b7e07192c7cd07efaf66a8e231e3162edfc002787339af1633</originalsourceid><addsrcrecordid>eNptkM1LAzEQxYMoWLQn_4GAR9maj-7O1psUv6BSED2H7Gbipmw3a7K16F9vSotePM2D-fFm3iPkgrMJ5zNxXa30RDAhJhKOyEiwvMimRVkc_2ooT8k4xhVjjJeCw5SNyPLZG21d51pqfaA9-r5FunVDQ2PduG_fNwE7p2laBmz1gIYaF30wGOIN1XTu6yboDukLfjrcnpMTq9uI48M8I2_3d6_zx2yxfHia3y6ympcwZHk1w_QBslwA2LxKClKGGmrDAK22RaFLFJKj5IVAY2vGBJQg5UxbXkh5Ri73vn3wHxuMg1r5TejSSSWAwRQSLxJ1tafq4GMMaFUf3FqHL8WZ2pWmUmlqV5qSkOjsQOt1FZx5xz_T__gfKTxtXg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2707470022</pqid></control><display><type>article</type><title>Modafinil for people with schizophrenia or related disorders: a Cochrane Review</title><source>Cambridge Journals</source><source>Alma/SFX Local Collection</source><creator>Ortiz-Orendain, Javier ; Covarrubias-Castillo, Sergio A. ; Vazquez-Alvarez, Alan Omar ; Castiello-de Obeso, Santiago ; Arias Quiñones, Gustavo E. ; Seegers, Maya ; Colunga-Lozano, Luis Enrique</creator><creatorcontrib>Ortiz-Orendain, Javier ; Covarrubias-Castillo, Sergio A. ; Vazquez-Alvarez, Alan Omar ; Castiello-de Obeso, Santiago ; Arias Quiñones, Gustavo E. ; Seegers, Maya ; Colunga-Lozano, Luis Enrique</creatorcontrib><description>Regarding the effect of modafinil on cognitive function, the trials did not report clinically important change data, but one study reported endpoint scores on the MATRICS Consensus Cognitive Battery (MCCB): in this study we found no clear difference in scores between modafinil and placebo treatment groups (MD −3.10, 95% CI −10.9 to 4.7; participants = 48; studies = 1, very low-quality evidence). None of the trials reported clinically important change in quality of life, but one study did report quality of life using endpoint scores on the Quality of Life Inventory, finding no clear difference between treatment groups (MD −0.2, 95% CI −1.18 to 0.78; participants = 20; studies = 1, very low-quality evidence). [...]one study reported data for number of participants needing hospitalisation: one participant in each group was hospitalised (RR 0.84, 95% CI 0.06 to 12.42; participants = 35; studies = 1, very low-quality evidence).</description><identifier>ISSN: 2056-4678</identifier><identifier>EISSN: 2056-4686</identifier><identifier>DOI: 10.1192/bja.2022.37</identifier><language>eng</language><publisher>Cambridge, UK: Cambridge University Press</publisher><subject>Antipsychotics ; Bias ; Clinical trials ; Cochrane corner ; Cognitive ability ; General Adult ; Psychosis ; Psychotropic drugs ; Quality of life ; Schizophrenia</subject><ispartof>BJPsych advances, 2022-09, Vol.28 (5), p.280-280</ispartof><rights>Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.cambridge.org/core/product/identifier/S2056467822000378/type/journal_article$$EHTML$$P50$$Gcambridge$$H</linktohtml><link.rule.ids>164,315,782,786,27931,27932,55635</link.rule.ids></links><search><creatorcontrib>Ortiz-Orendain, Javier</creatorcontrib><creatorcontrib>Covarrubias-Castillo, Sergio A.</creatorcontrib><creatorcontrib>Vazquez-Alvarez, Alan Omar</creatorcontrib><creatorcontrib>Castiello-de Obeso, Santiago</creatorcontrib><creatorcontrib>Arias Quiñones, Gustavo E.</creatorcontrib><creatorcontrib>Seegers, Maya</creatorcontrib><creatorcontrib>Colunga-Lozano, Luis Enrique</creatorcontrib><title>Modafinil for people with schizophrenia or related disorders: a Cochrane Review</title><title>BJPsych advances</title><addtitle>BJPsych advances</addtitle><description>Regarding the effect of modafinil on cognitive function, the trials did not report clinically important change data, but one study reported endpoint scores on the MATRICS Consensus Cognitive Battery (MCCB): in this study we found no clear difference in scores between modafinil and placebo treatment groups (MD −3.10, 95% CI −10.9 to 4.7; participants = 48; studies = 1, very low-quality evidence). None of the trials reported clinically important change in quality of life, but one study did report quality of life using endpoint scores on the Quality of Life Inventory, finding no clear difference between treatment groups (MD −0.2, 95% CI −1.18 to 0.78; participants = 20; studies = 1, very low-quality evidence). [...]one study reported data for number of participants needing hospitalisation: one participant in each group was hospitalised (RR 0.84, 95% CI 0.06 to 12.42; participants = 35; studies = 1, very low-quality evidence).</description><subject>Antipsychotics</subject><subject>Bias</subject><subject>Clinical trials</subject><subject>Cochrane corner</subject><subject>Cognitive ability</subject><subject>General Adult</subject><subject>Psychosis</subject><subject>Psychotropic drugs</subject><subject>Quality of life</subject><subject>Schizophrenia</subject><issn>2056-4678</issn><issn>2056-4686</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNptkM1LAzEQxYMoWLQn_4GAR9maj-7O1psUv6BSED2H7Gbipmw3a7K16F9vSotePM2D-fFm3iPkgrMJ5zNxXa30RDAhJhKOyEiwvMimRVkc_2ooT8k4xhVjjJeCw5SNyPLZG21d51pqfaA9-r5FunVDQ2PduG_fNwE7p2laBmz1gIYaF30wGOIN1XTu6yboDukLfjrcnpMTq9uI48M8I2_3d6_zx2yxfHia3y6ympcwZHk1w_QBslwA2LxKClKGGmrDAK22RaFLFJKj5IVAY2vGBJQg5UxbXkh5Ri73vn3wHxuMg1r5TejSSSWAwRQSLxJ1tafq4GMMaFUf3FqHL8WZ2pWmUmlqV5qSkOjsQOt1FZx5xz_T__gfKTxtXg</recordid><startdate>202209</startdate><enddate>202209</enddate><creator>Ortiz-Orendain, Javier</creator><creator>Covarrubias-Castillo, Sergio A.</creator><creator>Vazquez-Alvarez, Alan Omar</creator><creator>Castiello-de Obeso, Santiago</creator><creator>Arias Quiñones, Gustavo E.</creator><creator>Seegers, Maya</creator><creator>Colunga-Lozano, Luis Enrique</creator><general>Cambridge University Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>M2M</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>202209</creationdate><title>Modafinil for people with schizophrenia or related disorders: a Cochrane Review</title><author>Ortiz-Orendain, Javier ; Covarrubias-Castillo, Sergio A. ; Vazquez-Alvarez, Alan Omar ; Castiello-de Obeso, Santiago ; Arias Quiñones, Gustavo E. ; Seegers, Maya ; Colunga-Lozano, Luis Enrique</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c187t-5b9e217e05277f5b7e07192c7cd07efaf66a8e231e3162edfc002787339af1633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antipsychotics</topic><topic>Bias</topic><topic>Clinical trials</topic><topic>Cochrane corner</topic><topic>Cognitive ability</topic><topic>General Adult</topic><topic>Psychosis</topic><topic>Psychotropic drugs</topic><topic>Quality of life</topic><topic>Schizophrenia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ortiz-Orendain, Javier</creatorcontrib><creatorcontrib>Covarrubias-Castillo, Sergio A.</creatorcontrib><creatorcontrib>Vazquez-Alvarez, Alan Omar</creatorcontrib><creatorcontrib>Castiello-de Obeso, Santiago</creatorcontrib><creatorcontrib>Arias Quiñones, Gustavo E.</creatorcontrib><creatorcontrib>Seegers, Maya</creatorcontrib><creatorcontrib>Colunga-Lozano, Luis Enrique</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Psychology Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>BJPsych advances</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ortiz-Orendain, Javier</au><au>Covarrubias-Castillo, Sergio A.</au><au>Vazquez-Alvarez, Alan Omar</au><au>Castiello-de Obeso, Santiago</au><au>Arias Quiñones, Gustavo E.</au><au>Seegers, Maya</au><au>Colunga-Lozano, Luis Enrique</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Modafinil for people with schizophrenia or related disorders: a Cochrane Review</atitle><jtitle>BJPsych advances</jtitle><addtitle>BJPsych advances</addtitle><date>2022-09</date><risdate>2022</risdate><volume>28</volume><issue>5</issue><spage>280</spage><epage>280</epage><pages>280-280</pages><issn>2056-4678</issn><eissn>2056-4686</eissn><abstract>Regarding the effect of modafinil on cognitive function, the trials did not report clinically important change data, but one study reported endpoint scores on the MATRICS Consensus Cognitive Battery (MCCB): in this study we found no clear difference in scores between modafinil and placebo treatment groups (MD −3.10, 95% CI −10.9 to 4.7; participants = 48; studies = 1, very low-quality evidence). None of the trials reported clinically important change in quality of life, but one study did report quality of life using endpoint scores on the Quality of Life Inventory, finding no clear difference between treatment groups (MD −0.2, 95% CI −1.18 to 0.78; participants = 20; studies = 1, very low-quality evidence). [...]one study reported data for number of participants needing hospitalisation: one participant in each group was hospitalised (RR 0.84, 95% CI 0.06 to 12.42; participants = 35; studies = 1, very low-quality evidence).</abstract><cop>Cambridge, UK</cop><pub>Cambridge University Press</pub><doi>10.1192/bja.2022.37</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2056-4678 |
| ispartof | BJPsych advances, 2022-09, Vol.28 (5), p.280-280 |
| issn | 2056-4678 2056-4686 |
| language | eng |
| recordid | cdi_proquest_journals_2707470022 |
| source | Cambridge Journals; Alma/SFX Local Collection |
| subjects | Antipsychotics Bias Clinical trials Cochrane corner Cognitive ability General Adult Psychosis Psychotropic drugs Quality of life Schizophrenia |
| title | Modafinil for people with schizophrenia or related disorders: a Cochrane Review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T22%3A33%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Modafinil%20for%20people%20with%20schizophrenia%20or%20related%20disorders:%20a%20Cochrane%20Review&rft.jtitle=BJPsych%20advances&rft.au=Ortiz-Orendain,%20Javier&rft.date=2022-09&rft.volume=28&rft.issue=5&rft.spage=280&rft.epage=280&rft.pages=280-280&rft.issn=2056-4678&rft.eissn=2056-4686&rft_id=info:doi/10.1192/bja.2022.37&rft_dat=%3Cproquest_cross%3E2707470022%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2707470022&rft_id=info:pmid/&rft_cupid=10_1192_bja_2022_37&rfr_iscdi=true |